Search

Displaying results 2471 - 2480 of 10000 in total
  1. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. … The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML).

  2. Drug

    Brentuximab vedotin

    go.drugbank.com/drugs/DB08870
    ApprovedInvestigational

    [L1737] The U.S. … [L1737] The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care.

    Synonyms: Moab, chimeric, SGN-30, to CD30 antigen
  3. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    [A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production. … Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying

  4. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia … due to non-selective steroidal activities [A275513, A275514].

  5. Drug

    Halazepam

    go.drugbank.com/drugs/DB00801
    ApprovedIllicitWithdrawn

    [A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. … [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]

  6. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    [A260256] DMD tends to be more prevalent in males. … It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).

  7. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    [A261826] In fact, it has been observed that antigen-activated T cells within peripheral lymphoid organs can transiently downregulate S1P receptor levels to facilitate immune cells trafficking into the … [A261826] Therefore, S1P receptor modulators like etrasimod were investigated in treating immune-mediated diseases like ulcerative colitis where a high level of inflammatory T cells is present in the gastrointestinal

    Categories: Sphingosine-1-phosphate (S1P) receptor modulators
  8. Drug

    Panitumumab

    go.drugbank.com/drugs/DB01269
    ApprovedInvestigational

    Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.

    Categories: Epidermal Growth Factor Receptor Antagonist, EGFR (Epidermal Growth Factor Receptor) inhibitors
  9. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    (NMDA) receptor,[A18263] indicating a role for the glutamatergic system in the pathophysiology of ADHD. … The non-stimulant norepinephrine/dopamine reuptake inhibitor [DB01156] (commonly used for the treatment of depression and for smoking cessation) has also been shown to be effective in the treatment of

  10. Target

    P2X purinoceptor 7

    go.drugbank.com/bio_entities/BE0009814
    TargetHumans

    ATP-gated nonselective transmembrane cation channel that requires high millimolar concentrations of ATP for activation (PubMed:17483156, PubMed:25281740, PubMed:9038151). Upon ATP binding, it rapidly opens to allow the influx of small ca...

    Synonyms: ATP receptor, P2Z receptor